Acute Treatment of Disabling and Nondisabling Minor Ischemic Stroke: Expert Guidance for Clinicians
Authors:
- Federico De SantisFSFederico De Santis
- Matteo FoschiMFMatteo Foschi
- Lucio D’aNnaLDLucio D’aNna
- Shelagh B. CouttsSCShelagh B. Coutts
- Urs FischerUrs Fischer
- Pooja KhatriPKPooja Khatri
- Ahmed NasreldeinANAhmed Nasreldein
- Octávio Marques Pontes-NetoOPOctávio Marques Pontes-Neto
- Thanh N. NguyenThanh N. Nguyen
- Else Charlotte SandsetESElse Charlotte Sandset
- Georgios TsivgoulisGeorgios Tsivgoulis
- Guillaume TurcGTGuillaume Turc
Top Cited Papers
Open Access
- 1 February 2026
- journal article
- review article
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (2) , 549-559
Abstract
Minor ischemic strokes, usually defined as acute ischemic strokes with National Institutes of Health Stroke Scale score ≤5, account for over half of all cases and are often underestimated due to initially mild symptoms. Yet up to 30% of patients develop disability within 90 days, challenging the notion of a benign course. This guidance offers a pragmatic, scenario-based framework for acute minor ischemic stroke management, considering symptom severity (disabling versus nondisabling), eligibility for reperfusion, and presence of large vessel occlusion. Drawing from randomized trials, real-world evidence, and international guidelines, we examine therapeutic strategies, including dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor, anticoagulation, intravenous thrombolysis, and endovascular treatment. Intravenous thrombolysis is preferred for disabling symptoms within 4.5 hours of symptom onset, whereas dual antiplatelet therapy remains standard for noncardioembolic, nondisabling events. For cardioembolic minor ischemic stroke ineligible for reperfusion, early anticoagulation within 48 hours appears safe and beneficial. Evidence for routine endovascular treatment in minor ischemic stroke with large vessel occlusion remains limited and controversial. We also address management of rapidly improving yet disabling symptoms and postreperfusion antithrombotic strategies, emphasizing individualized care and the need for further research.Keywords
This publication has 114 references indexed in Scilit:
- Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial FibrillationJAMA Neurology, 2025
- Prourokinase vs Standard Care for Patients With Mild Ischemic StrokeJAMA Neurology, 2025
- Early vs Late Anticoagulation in Minor, Moderate, and Major Ischemic Stroke With Atrial FibrillationJAMA Neurology, 2024
- Comparison of Dual Antiplatelet Therapies for Minor, Nondisabling, Acute Ischemic Stroke: A Bayesian Network Meta-AnalysisJAMA Network Open, 2024
- Dual Antiplatelet Therapy vs Alteplase for Patients With Minor Nondisabling Acute Ischemic StrokeJAMA, 2023
- Prediction of Early Neurological Deterioration in Individuals With Minor Stroke and Large Vessel Occlusion Intended for Intravenous Thrombolysis AloneJAMA Neurology, 2021
- Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic DeficitsJAMA, 2018
- Association BetweenCYP2C19Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic AttackJAMA, 2016
- Early Risk of Stroke After Transient Ischemic AttackArchives of internal medicine (1960), 2007
- Short-term Prognosis After Emergency Department Diagnosis of TIAJAMA, 2000